Christopher Stanley Krawtschuk
CFO and Principal Financial & Accounting OfficerMr. Christopher Stanley Krawtschuk, also known as Chris, has been a Director of Acacia Pharma Limited since February 16, 2026. He is Chief Financial Officer and Principal Financial & Accounting Officer of Eagle Pharmaceuticals, Inc. from November 11, 2024. Mr. Krawtschuk served as Chief Financial Officer and Treasurer at bluebird bio, Inc since November 07, 2022 and served as its Principal Accounting Officer since November 07, 2022 until June 10, 2024. He joined bluebird bio, Inc. in 2022. He served as Director of Sofie Biosciences, Inc. until February 2023. He had been Chief Financial Officer of Jubilant Pharma Limited since February 1, 2021 to October 2022. Mr. Krawtschuk was Chief Financial Officer of the US subsidiary of Morphosys, a listed company in German Stock Exchange with ADS in Nasdaq. In 2018, Mr. Krawtschuk served as North American Controller at Unilever. He has worked for 15 years with PWC, US; first 6 years in the Audit practice and the remaining 9 years in Accounting Advisory and Capital Markets practice. He has assisted Verizon acquiring Bell labs; Pfizer acquiring Wyeth, selling the animal health product business for Pfizer; selling the nutrition business for Pfizer to Nestle and a number of capital raise transactions including convertibles, bonds, structured papers, etc. He was doing deals in conjunction with the M&A bankers. Subsequently, he joined Pfizer as a VP and Lead Divisional Controller to run the global accounting operations for commercial, manufacturing, R&D and treasury functions. He has authored American Institute of CPA “Guide on IPR&D (Business Combinations and Asset Acquisitions)” and several PWC publications on business combinations and divestitures. Mr. Krawtschuk began his financial career at PricewaterhouseCoopers where he held several positions of increasing responsibility from 2001 to 2016. He was awarded NYM Divestiture Service Leader for Capital Markets and Accounting Advisory Services (PwC). Mr. Krawtschuk is B.Sc-Accounting from William Paterson University and is a Certified Public Accountant from USA.
Positions
- Company NameEagle Pharmaceuticals, Inc.Stock CodeEGRXPositionCFO and Principal Financial & Accounting OfficerColleagues
- MGMichael GravesCEO & Chairman
- DODaniel O'ConnorExecutive VP, Chief Strategy Officer & Head of Corporate Development
- VRValentin R. CurtSenior Vice President of Clinical Drug Development
- RLRobert L. GlenningIndependent Director
- RARichard A. EdlinIndependent Director
- JKJennifer K. SimpsonLead Independent Director
- SBSteven B. RatoffDirector
